Liquid Biopsy Market Growth By Product, Application Biomarkers - Forecast 2022
According to the market research report Liquid Biopsy Market is expected to reach $2,047.9 Million by 2022 from an estimated $715.7 Million in 2017, at a CAGR of 23.4%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350
Some
of the key factors driving the growth of this market include increasing
preference for noninvasive procedures, increasing prevalence of cancer
and availability of funding for liquid biopsy R&D.
The key
players in the global liquid biopsy market are QIAGEN N.V.
(Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US),
Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic
Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc.
(US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc.
(US), RainDance Technologies, Inc. (US), and MDx Health SA (US).
By clinical application, the therapy selection segment is expected to account fors the largest market share in 2017.
Based
on clinical application, the liquid biopsy market is segmented into
early cancer screening, therapy selection, treatment monitoring, and
recurrence monitoring. The therapy selection segment is expected to
account for the largest share of the liquid biopsy devices market in
2017. This is due to the ability of therapy selection to detect
advanced-stage cancers (stage III and IV), followed by increasing
studies on liquid biopsy and advancements made in this field to also aid
in detection of early-stage cancers.
By application, the cancer
segment is expected to account for the largest market share in 2017.
Based on application, the market is segmented into cancer and non-cancer
applications (which includes reproductive health and organ transplant
diagnostics). In 2017, cancer applications segment is expected to
account for the largest share of the liquid biopsy market.
By
circulating biomarkers, circulating tumor cells is expected to account
for the largest market share in 2017. Based on circulating biomarkers
the market is categorized into circulating tumor cells (CTCs),
circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular
vesicles (EVs), and other circulating biomarkers. In 2017, the
circulating tumor cells segment is expected to account for the largest
share of the liquid biopsy market.
By product, the assay kits
segment is expected to account for the largest share of the market in
2017. On the basis of product, the market is broadly segmented into
assays kits, instruments, and services. In 2017, the assay kits segment
is expected to account for the largest share of this market.
Request For Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350
North
America is expected to account for the largest share of the global
liquid biopsy market in 2017, while Asia Pacific is expected to witness
the highest growth during 2017 to 2022.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com
Comments
Post a Comment